The Technical Analyst
Merus NV [MRUS]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Merus NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.37% $22.33
Last updated: 3 jul 2022 - 19:57
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 972.47 mill |
| EPS: | -1.867 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 43.55 mill |
| Avg Daily Volume: | 0.367 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$28.58 (27.98%) $6.25 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $1.487 ( +/- 6.66%) Range: 20.84 - 23.82 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-01 | Shuman Harry | Sell | 2 500 | Restricted Share Unit |
| 2022-06-01 | Shuman Harry | Sell | 575 | Common Shares |
| 2022-06-01 | Shuman Harry | Buy | 2 500 | Common Shares |
| 2022-05-31 | Iwicki Mark T | Buy | 16 604 | Share option (right to buy) |
| 2022-05-31 | Perry Gregory D | Buy | 16 604 | Share option (right to buy) |
| INSIDER POWER |
|---|
| -8.16 |
| Last 100 transactions |
| Buy: 3 806 205 | Sell: 3 624 056 |
Forecast:
16:00 - $22.33
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $22.33
Forecast 2: 16:00 - $22.33
Forecast 3: 16:00 - $22.33
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $22.33 (-1.37% ) |
| Volume | 0.166 mill |
| Avg. Vol. | 0.367 mill |
| % of Avg. Vol | 45.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRUS
22 Signals | Accuracy: 31.82% | Accuracy Buy: 36.36% | Accuracy Sell: 27.27%
Avg return buy: -0.11 % | Avg return sell: 0.25 %
$1 invested is now $0.99 or -1.26% since 30-06-22
| Date | Signal | @ | Closed | % | Jun 30 - 09:50 | sell | $22.05 | $22.17 @ Jun 30 - 12:34 | 0.54% |
|---|---|---|---|---|
| Jun 30 - 09:45 | buy | $22.10 | $22.05 @ Jun 30 - 09:50 | -0.23% |
| Jun 30 - 09:30 | sell | $22.10 | $22.10 @ Jun 30 - 09:45 | 0.00% |
| Jun 30 - 09:29 | buy | $22.11 | $22.10 @ Jun 30 - 09:30 | -0.05% |
MRUS
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 98 full-time employees. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Latest Press Releases
2022-06-05 11:00:00 - Press Release
Merus Presents Clinical Data On Zenocutuzumab (zeno) In Nrg1-fusion (nrg1+) Cancer At The 2022 American Society Of Clinical Oncology (asco) Annual Meeting (oral Abstract)
Utrecht, the netherlands and cambridge, mass., june 05, 2022 (globe newswire) -- merus n.v. (nasdaq: mrus) (“merus”, “the company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (biclonics® and triclonics®), today announced interim efficacy data as of an april 12, 2022 data cutoff date, from the phase 1/2 enrgy trial and early access program (eap) of the bispecific antibody zeno in patients with nrg1+ cancer presented virtually by lead author, dr. alison schram of memorial sloan kettering cancer center (mskcc) at the 2022 asco annual meeting.
2022-06-03 08:00:00 - Press Release
Merus To Participate In A Fireside Chat At The Jefferies Healthcare Conference
Utrecht, the netherlands and cambridge, mass., june 03, 2022 (globe newswire) -- merus n.v. (nasdaq: mrus), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (biclonics® and triclonics®), today announced that bill lundberg, m.d., president, chief executive officer of merus, will participate in a fireside chat at the jefferies healthcare conference on friday, june 10 at 12:45 p.m. et.
2022-05-26 17:00:00 - Press Release
Merus Announces Publication Of Abstract Of Zenocutuzumab In Nrg1-fusion (nrg1+) Cancer At The 2022 American Society Of Clinical Oncology (asco) Annual Meeting
- robust 34% overall response rate and 9.1 months median duration of response across multiple nrg1+ tumor types
2022-05-09 16:29:00 - Press Release
Merus Announces Financial Results For The First Quarter 2022 And Provides Business Update
- zenocutuzumab clinical abstract selected for oral presentation at the 2022 american society of clinical oncology (asco) annual meeting - company to host investor call on sunday, june 5 at 6:00 p.m. ct - clinical data update of petosemtamab (peto) and mcla-129 planned for second half of 2022
2022-04-25 08:00:00 - Press Release
Merus Announces Publication In Nature Cancer On Petosemtamab's (mcla-158) Unique Mechanism Of Action
Utrecht, the netherlands and cambridge, mass., april 25, 2022 (globe newswire) -- merus n.v. (nasdaq: mrus) (“merus”, “the company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (biclonics® and triclonics®), today announced publication of a preclinical report on petosemtamab (peto, mcla-158: lgr5 x egfr biclonics®) in the journal nature cancer . the publication will be available at 11:00 a.m. et today. the report describes the use of the company's biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of peto, a bispecific antibody targeting the epidermal growth factor receptor (egfr) and the leucine-rich repeat containing g protein-coupled receptor (lgr5)...
Latest News
2022-06-30 11:33:38 - Seeking Alpha
Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. I provide a recap of our thesis on this promising platform technology play in the oncology space.
2022-05-26 11:18:27 - Zacks Investment Research
Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround
Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2022-05-25 10:48:21 - Zacks Investment Research
Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now.
2022-05-17 08:00:00 - GlobeNewsWire
Merus to Present at the H.C. Wainwright Global Investment Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference.
2022-05-09 20:18:31 - Zacks Investment Research
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-02-03 08:00:00 - GlobeNewsWire
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
2021-11-02 20:40:17 - Zacks Investment Research
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-10-28 16:50:57 - Zacks Investment Research
Will Merus N.V. (MRUS) Report Negative Q3 Earnings?
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-10-08 06:26:03 - Zacks Investment Research
Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2021-10-07 21:43:36 - Pulse2
MRUS Stock: Why It Substantially Increased Today
The stock price Merus NV (NASDAQ: MRUS) increased by over 35% today. This is why it happened.